What is “beyond rule of five” chemical space?

In 1997 Christopher Lipinski and colleagues analysed compounds that had reached clinical trials and proposed a simple guide for oral absorption, now known as the rule of five (Ro5). Poor absorption or permeation becomes more likely when a molecule has more than one of these:

• molecular weight above 500 Da;
• calculated logP (lipophilicity) above 5;
• more than 5 hydrogen-bond donors;
• more than 10 hydrogen-bond acceptors.

The rule (all its cut-offs are multiples of five) became a standard filter for screening libraries.

Drugs that break the rule

A notable set of approved oral drugs violates the Ro5 — many of them natural products, macrocycles or other large molecules targeting difficult proteins. Chemists call this region beyond rule of five (bRo5). Commonly quoted bRo5 ranges are roughly:

How bRo5 drugs get absorbed

Size alone does not decide absorption. What matters is how polar the molecule appears when it crosses a membrane. Many successful bRo5 drugs are conformationally flexible in a controlled way: they form internal hydrogen bonds and fold to hide polar groups in fatty environments, then open up again in water. This behaviour is called chameleonicity and is discussed in membrane permeability.

What this means for design

For bRo5 projects, simple 2D property filters are not enough. Teams measure permeability early, use 3D descriptors that account for conformation, and favour rigid, pre-organised scaffolds such as macrocycles over long floppy chains of the same weight.